Q2 and First Half Year Results ended 30 June 2026

CelLBxHealth plc

("CelLBxHealth" or "the Company")

Q2 and First Half Year Results ended 30 June 2026

Q2 revenue increased 100% over Q1 and annualised burn rate reduced by 61%

Guildford, UK and Plymouth Meeting, U.S. - 15 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces its unaudited Q2 and the interim results for the six months ended 30 June 2026.

CelLBxHealth Executive Chairman, Jan Groen, commented:

"We have created a leaner, more commercially focused business, strengthened our strategic partnerships and the strong growth in Q2 revenue is an early sign of the successful implementation of our revised commercial strategy. Our unique live CTC platform addresses an important unmet clinical need, and we remain focused on disciplined execution as we convert this growing opportunity into sustainable revenue growth."

Financial Highlights

Operational Highlights

Post closing events

Outlook

For further information:

Notes for editors 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.

CELLBXHEALTH PLC

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2026

CELLBXHEALTH PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2026

CELLBXHEALTH PLC

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

CELLBXHEALTH PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 JUNE 2026

CELLBXHEALTH PLC

NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION

FOR THE PERIOD ENDED 30 JUNE 2026

1. Preliminary announcement

The Condensed Interim Financial Information is the unaudited interim consolidated financial information (the "Condensed Interim Financial Information") of CelLBxHealth plc, a company incorporated and domiciled in Great Britain and its subsidiaries (together referred to as the "Group") for the six-month period ended 30 June 2026 (the "interim period").

The Condensed Interim Financial Information should be read in conjunction with the Financial Statements of the Group for the year ended 31 December 2025, which have been prepared in accordance with UK-adopted international accounting standards. New and revised accounting standards and interpretations that became effective in the period did not have or are not expected to have a significant impact on the Group. Where necessary, comparative information has been reclassified or expanded from the previously reported Condensed Interim Financial Information to take into account any presentational changes which were made in the Annual Report and Financial Statements to 31 December 2025 and which may be made in the Annual Report and Financial Statements to 31 December 2026.

The accounting policies used in the preparation of the Condensed Interim Financial Information for the six months ended 30 June 2026 are in accordance with UK-adopted accounting standards and are consistent with those which will be adopted in the Financial Statements for the year ended 31 December 2026. While the Condensed Interim Financial Information has been prepared in accordance with the recognition and measurement criteria of UK-adopted international accounting standards, these Financial Statements do not contain sufficient information to comply with UK-adopted international accounting standards.

The Condensed Interim Financial Information does not constitute statutory financial statements as defined in section 434 of the Companies Act 2006 and is unaudited and has not been reviewed. The comparative information for the six months ended 30 June 2025 is also unaudited. The comparative figures for the year ended 31 December 2025 have been extracted from the Group Financial Statements as filed with the Registrar of Companies. The report of the auditors on those Financial Statements was unqualified and did not contain statements under sections 498(2) or (3) of the Companies Act 2006, although it included a material uncertainty related to going concern. The Directors have updated their assessment of going concern for the six months ended 30 June 2026 and their conclusions are set out below.

The Condensed Interim Financial Information was approved by the Board and authorised for issue on 14 July 2026.

Going concern

The Financial Statements have been prepared on a going concern basis. In adopting this basis, the Directors have assessed the Group's ability to continue as a going concern for a period of at least 12 months from the date of approval of these Financial Statements, taking into account all available information.

The Group's business activities, together with the factors likely to affect its future development, performance and financial position, are set out in the Executive Chairman's letter and the Chief Executive's Statement.

At 30 June 2026, the Group held cash and cash equivalents of £2.9 million. The Group funds its operations through existing cash reserves, revenues generated across its three commercial pillars, and through equity financing where appropriate.

The Directors have prepared a detailed monthly forecast to 31 December 2027, incorporating severe but plausible downside scenarios. These scenarios assume a material reduction in forecast revenues, delays in the conversion of pipeline opportunities, and limited access to external financing, with discretionary expenditure reductions applied to partially offset the impact. The Group anticipates revenue growth in FY2026, weighted towards the second half of the year, with a return to material revenue growth in FY2027 dependent on the successful and timely conversion of a number of significant commercial opportunities. Based on current cash resources, the Group has funding into Q2 2027.

The Directors believe several potential funding sources are available to the Group, including revenues, commercial milestones, licensing income, and debt or equity financing. However, based on current forecasts, the Group will require additional funding to continue operations beyond Q2 2027. There can be no certainty that such funding will be obtained on acceptable terms, or at all.

The Group's forecasts are dependent upon the successful and timely conversion of a number of significant commercial opportunities into revenue, the timing and extent of which remain uncertain. A significant proportion of forecast revenues is concentrated within a relatively small number of opportunities and customers, and many pipeline opportunities remain at proposal stage. There can be no certainty that forecast revenues will be achieved in line with management's expectations. These conditions, together with the requirement for additional funding beyond Q2 2027, represent a material uncertainty that may cast significant doubt on the Group's ability to continue as a going concern. Notwithstanding this, the Directors have a reasonable expectation that the Group will be able to secure the necessary funding and meet its liabilities as they fall due. As a result, the Financial Statements continue to be prepared on a going concern basis and do not include any adjustments that would result if the Group were unable to continue as a going concern.

Critical accounting estimates and judgements

The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. There were no areas of significant judgement or key sources of estimation uncertainty in preparing these Financial Statements.

2. Tax

The Group undertakes research and development activities. During the period the Group recognised income under the UK merged Research and Development tax relief scheme within Other operating income. The comparative period reflects claims made under the former SME R&D tax relief regime, which were presented within taxation.

3. Loss per share attributable to owners of the parent

Basic and diluted loss per share is calculated by dividing the loss attributable to owners of the parent of £2.7 million (six months to 30 June 2025: loss £9.3 million, year ended 31 December 2025: loss £19.5 million) by the weighted average number of ordinary shares in issue during the period.

As the Group reported a loss in the current and comparative periods, potentially dilutive share options have not been included in the calculation of diluted loss per share as they are anti-dilutive. As a result, diluted loss per share is equal to basic loss per share.

The weighted average number of ordinary shares used in the calculation was 1,136,767,299 (six months to 30 June 2025: 322,528,409; year ended 31 December 2025: 353,834,856).

4. Share capital

The Company has one class of ordinary shares which carry no right to fixed income. The deferred shares carry no voting rights and have restricted rights to dividends and on a return of capital as set out in the Company's Articles of Association.

At 30 June 2026, the Company had 1,139,402,658 ordinary shares of £0.0005 each and 322,641,668 deferred shares of £0.0995 each in issue and fully paid.

5. Shareholder communications

This announcement is being sent to all shareholders on the register at 15 July 2026. Copies of this announcement are posted on the Company's website https://cellbxhealth.com/ and are available from the Company's registered office: 10 Nugent Road, Surrey Research Park, Guildford, Surrey, GU2 7AF.